Last checked at 
24 Aug 2017 15:15
24 August 2017
BIOPHARMA CREDIT PLC
("BPC" or the "Group")
NOTICE OF RESULTS - PLEASE NOTE NEW TIMINGS FOR THE MEETING
BioPharma Credit PLC (LSE: BPC), the life sciences debt investment trust, will announce its audited Half Year Results for the period ending 30 June 2017, on Thursday 21 September 2017.
A management presentation will be held at 10:30 at Goldman Sachs, Peterborough Court, 133 Fleet Street, London EC4A 2BB. A conference call facility will also be available.
To confirm your attendance, or request conference call details, RSVP to tmitchell@bellpottinger.com by Wednesday 13 September 2017.
-Ends-
For further information, please contact:
BioPharma Credit | |
Alex v. Perfall (Royalty Pharma) Jeff Caprio (Pharmakon Advisors) | +1 (212) 883 2263 |
J.P. Morgan Cazenove | |
William Simmonds Oliver Kenyon | +44 (0)20 7742 4000 |
|
|
Goldman Sachs |
|
Shomick Bhattacharya Charlie Lytle Tom Hartley | +44 (0)20 7774 1000 |
|
|
Bell Pottinger | |
David Rydell Ian Shackleton | +44 (0)20 3772 2602 |
About BioPharma Credit:
Shares of BioPharma Credit PLC were successfully admitted to trading on the Specialist Fund Segment of the Main Market of the London Stock Exchange on 27 March 2017: one of the largest IPO's in the London market this year with a market capitalisation just under $800m. Gross proceeds included a portfolio of $338.6 million in seed assets, comprised of loans secured by royalties and other cash flows from sales of close to 30 life sciences products.
The company provides investors with an opportunity to gain uncorrelated returns and exposure to the fast-growing life sciences industry, through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products.
BioPharma Credit's primary objective is to generate predictable income for shareholders over the long term. Once substantially invested, BioPharma Credit will target an annual dividend yield of 7 per cent. (calculated by reference to the Issue Price), and a net total return on NAV of 8 to 9 per cent. per annum in the medium term. Pharmakon Advisors, the fund's Investment Manager, was founded in 2009 and has invested US$1.3 billion in 20 transactions across four funds. The first three funds are now fully invested. Drawing upon the expertise and successful track record of Pharmakon Advisors, the fund enjoys access to its extensive, life sciences industry-focused knowledge and contacts to source, analyse and structure attractive debt investments.
Through a shared services agreement with Royalty Pharma, founded in 1996, the Investment Manager will be able to rely on the complementary expertise of the team behind the market leading investor in pharmaceutical royalties.
More details are available on www.bpcruk.com.